ResMed Inc. reported third-quarter revenues of $864.5 million, a 12% increase year-over-year, although it fell short of the projected $908.7 million. The company missed the earnings per share estimate of $1.44, with a reported $1.32 for the quarter, despite achieving a healthy net income of $179 million, a significant improvement from last year's loss. Strong performance in the U.S., Canada, and Latin America, alongside a declared quarterly cash dividend of $0.42 per share, highlights ResMed's ongoing commitment to innovation in digital health technologies.
“ResMed · expected revenues · $908.7 million”
“ResMed · third-quarter earnings per share estimate · $1.44”
“ResMed · expected revenues · for the third quarter of fiscal 2022 · $908.7 million”
“ResMed · expected earnings per share · for the third quarter of fiscal 2022 · $1.44”
“ResMed · has · chief executive officer · Mick Farrell”
“ResMed · has · chief financial officer · Brett Sandercock”
“ResMed (RMD) · came out with quarterly earnings of · earnings per share · $1.32”
“ResMed (RMD) · missed the Zacks Consensus Estimate of · earnings per share · $1.44”
“ResMed (RMD) · posted revenues of · quarterly revenues · $864.5 million”
“ResMed (RMD) · missed the Zacks Consensus Estimate by · percentage · 4.86%”
“ResMed (RMD) · has topped consensus revenue estimates · number of times · two”
“ResMed · currently has a Zacks Rank of · ranking · #3 (Hold)”